Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer.

Giannopoulou AF, Velentzas AD, Konstantakou EG, Avgeris M, Katarachia SA, Papandreou NC, Kalavros NI, Mpakou VE, Iconomidou V, Anastasiadou E, Kostakis IK, Papassideri IS, Voutsinas GE, Scorilas A, Stravopodis DJ.

Int J Mol Sci. 2019 Mar 14;20(6). pii: E1291. doi: 10.3390/ijms20061291. Review.

2.

Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.

Avgeris M, Tsilimantou A, Levis PK, Rampias T, Papadimitriou MA, Panoutsopoulou K, Stravodimos K, Scorilas A.

Carcinogenesis. 2019 Feb 27. pii: bgz045. doi: 10.1093/carcin/bgz045. [Epub ahead of print]

PMID:
30815670
3.

Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients.

Giannopoulou AF, Konstantakou EG, Velentzas AD, Avgeris SN, Avgeris M, Papandreou NC, Zoi I, Filippa V, Katarachia S, Lampidonis AD, Prombona A, Syntichaki P, Piperi C, Basdra EK, Iconomidou V, Papadavid E, Anastasiadou E, Papassideri IS, Papavassiliou AG, Voutsinas GE, Scorilas A, Stravopodis DJ.

Int J Mol Sci. 2019 Feb 21;20(4). pii: E937. doi: 10.3390/ijms20040937.

4.

Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk.

Christodoulou MI, Avgeris M, Kokkinopoulou I, Maratou E, Mitrou P, Kontos CK, Pappas E, Boutati E, Scorilas A, Fragoulis EG.

Sci Rep. 2019 Feb 6;9(1):1512. doi: 10.1038/s41598-018-37856-1.

5.

Where There Is Fire There Is SMOKE: A Scalable Edge Computing Framework for Early Fire Detection.

Avgeris M, Spatharakis D, Dechouniotis D, Kalatzis N, Roussaki I, Papavassiliou S.

Sensors (Basel). 2019 Feb 3;19(3). pii: E639. doi: 10.3390/s19030639.

6.

Semantic Interoperability for IoT Platforms in Support of Decision Making: An Experiment on Early Wildfire Detection.

Kalatzis N, Routis G, Marinellis Y, Avgeris M, Roussaki I, Papavassiliou S, Anagnostou M.

Sensors (Basel). 2019 Jan 27;19(3). pii: E528. doi: 10.3390/s19030528.

7.

The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.

Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, Kousidou E, Tzetis M, Kanavakis E, Stravodimos K, Manola KN, Pantelias GE, Scorilas A, Klinakis A.

EMBO Rep. 2019 Mar;20(3). pii: e46821. doi: 10.15252/embr.201846821. Epub 2019 Jan 21.

8.

Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12.

Kontos CK, Avgeris M, Vassilacopoulou D, Ardavanis A, Scorilas A.

Curr Pharm Biotechnol. 2018;19(13):1064-1075. doi: 10.2174/1389201019666181112101410.

PMID:
30417787
9.

Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients.

Avgeris M, Tsilimantou A, Levis PK, Tokas T, Sideris DC, Stravodimos K, Ardavanis A, Scorilas A.

Br J Cancer. 2018 Dec;119(12):1477-1486. doi: 10.1038/s41416-018-0320-6. Epub 2018 Oct 30.

PMID:
30374124
10.

miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers.

Panoutsopoulou K, Avgeris M, Scorilas A.

Expert Rev Mol Diagn. 2018 Nov;18(11):963-979. doi: 10.1080/14737159.2018.1538794. Epub 2018 Oct 29.

PMID:
30338716
11.

BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia.

Avgeris M, Stamati L, Kontos CK, Piatopoulou D, Marmarinos A, Xagorari M, Baka M, Doganis D, Anastasiou T, Kosmidis H, Gourgiotis D, Scorilas A.

Clin Chem Lab Med. 2018 Nov 27;56(12):2104-2118. doi: 10.1515/cclm-2018-0507.

PMID:
30016275
12.

Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.

Piatopoulou D, Avgeris M, Drakaki I, Marmarinos A, Xagorari M, Baka M, Pourtsidis A, Kossiva L, Gourgiotis D, Scorilas A.

Ann Hematol. 2018 Jul;97(7):1169-1182. doi: 10.1007/s00277-018-3292-y. Epub 2018 Mar 20.

PMID:
29556721
13.

miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.

Tsikrika FD, Avgeris M, Levis PK, Tokas T, Stravodimos K, Scorilas A.

Genes Chromosomes Cancer. 2018 Mar;57(3):150-161. doi: 10.1002/gcc.22516. Epub 2017 Dec 15.

PMID:
29181884
14.

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.

Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A.

Ann Oncol. 2017 Aug 1;28(8):1923-1933. doi: 10.1093/annonc/mdx206.

PMID:
28838214
15.

miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.

Piatopoulou D, Avgeris M, Marmarinos A, Xagorari M, Baka M, Doganis D, Kossiva L, Scorilas A, Gourgiotis D.

Br J Cancer. 2017 Sep 5;117(6):801-812. doi: 10.1038/bjc.2017.256. Epub 2017 Aug 8.

16.

Combining of ETHOS Operating Ergonomic Platform, Three-dimensional Laparoscopic Camera, and Radius Surgical System Manipulators Improves Ergonomy in Urologic Laparoscopy: Comparison with Conventional Laparoscopy and da Vinci in a Pelvi Trainer.

Tokas T, Gözen AS, Avgeris M, Tschada A, Fiedler M, Klein J, Rassweiler J.

Eur Urol Focus. 2017 Oct;3(4-5):413-420. doi: 10.1016/j.euf.2016.11.006. Epub 2016 Nov 26.

PMID:
28753821
17.

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.

Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenár É, Degardin M, Pateras IS, Langendijk JA, van Herpen CML, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB.

Ann Oncol. 2017 Sep 1;28(9):2213-2218. doi: 10.1093/annonc/mdx320.

PMID:
28651338
18.

miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma.

Kontos CK, Tsiakanikas P, Avgeris M, Papadopoulos IN, Scorilas A.

Mol Diagn Ther. 2017 Aug;21(4):453-464. doi: 10.1007/s40291-017-0270-3.

PMID:
28405803
19.

Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.

Tokas T, Avgeris M, Alamanis C, Scorilas A, Stravodimos KG, Constantinides CA.

J Cancer Res Clin Oncol. 2017 Mar;143(3):521-532. doi: 10.1007/s00432-016-2301-6. Epub 2016 Nov 17.

PMID:
27858162
20.

Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.

Avgeris M, Scorilas A.

Expert Opin Ther Targets. 2016 Jul;20(7):801-18. doi: 10.1517/14728222.2016.1147560. Epub 2016 Mar 4. Review.

PMID:
26941073
21.

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.

Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A.

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543. Epub 2015 Sep 25.

22.

Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.

Stamati L, Avgeris M, Kosmidis H, Baka M, Anastasiou T, Piatopoulou D, Scorilas A, Gourgiotis D.

J Cancer Res Clin Oncol. 2015 Nov;141(11):2023-36. doi: 10.1007/s00432-015-1982-6. Epub 2015 May 16.

PMID:
25982455
23.

Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.

Avgeris M, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG, Scorilas A.

Carcinogenesis. 2015 May;36(5):528-37. doi: 10.1093/carcin/bgv024. Epub 2015 Mar 24.

PMID:
25804644
24.

A new tumor suppressor role for the Notch pathway in bladder cancer.

Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A.

Nat Med. 2014 Oct;20(10):1199-205. doi: 10.1038/nm.3678. Epub 2014 Sep 7.

PMID:
25194568
25.
26.

Targeting kallikrein-related peptidases in prostate cancer.

Mavridis K, Avgeris M, Scorilas A.

Expert Opin Ther Targets. 2014 Apr;18(4):365-83. doi: 10.1517/14728222.2014.880693. Epub 2014 Feb 27. Review.

PMID:
24571737
27.

Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors.

Foutadakis S, Avgeris M, Tokas T, Stravodimos K, Scorilas A.

Urol Oncol. 2014 Jan;32(1):39.e29-36. doi: 10.1016/j.urolonc.2013.04.005. Epub 2013 Jun 18.

PMID:
23790536
28.

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.

Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A.

Br J Cancer. 2013 Jun 25;108(12):2573-81. doi: 10.1038/bjc.2013.250. Epub 2013 May 23.

29.

L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.

Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, Scorilas A, Lazaris A, Constantinides C.

BJU Int. 2012 Sep;110(6 Pt B):E267-73. doi: 10.1111/j.1464-410X.2012.11152.x. Epub 2012 May 9.

30.

Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.

Avgeris M, Mavridis K, Scorilas A.

Biol Chem. 2012 Apr;393(5):301-17. doi: 10.1515/hsz-2011-0260. Review.

PMID:
22505514
31.

Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.

Avgeris M, Papachristopoulou G, Polychronis A, Scorilas A.

Clin Proteomics. 2011 May 31;8(1):5. doi: 10.1186/1559-0275-8-5.

32.

Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.

Avgeris M, Stravodimos K, Scorilas A.

Prostate. 2011 Dec;71(16):1780-9. doi: 10.1002/pros.21395. Epub 2011 Apr 25.

PMID:
21520157
33.

Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues.

Papachristopoulou G, Avgeris M, Charlaftis A, Scorilas A.

Thromb Haemost. 2011 Jan;105(1):131-7. doi: 10.1160/TH10-02-0092. Epub 2010 Nov 5.

PMID:
21057706
34.

Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.

Avgeris M, Mavridis K, Scorilas A.

Biol Chem. 2010 May;391(5):505-11. doi: 10.1515/BC.2010.056. Review.

PMID:
20302518
35.

Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.

Mavridis K, Avgeris M, Koutalellis G, Stravodimos K, Scorilas A.

Cancer Sci. 2010 Mar;101(3):693-9. doi: 10.1111/j.1349-7006.2009.01450.x. Epub 2009 Nov 27.

36.

Expression analysis and study of KLK4 in benign and malignant breast tumours.

Papachristopoulou G, Avgeris M, Scorilas A.

Thromb Haemost. 2009 Feb;101(2):381-7.

PMID:
19190825
37.

Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.

Avgeris M, Koutalellis G, Fragoulis EG, Scorilas A.

Clin Biochem. 2008 Oct;41(14-15):1140-9. doi: 10.1016/j.clinbiochem.2008.04.026. Epub 2008 Jun 10.

PMID:
18586020

Supplemental Content

Loading ...
Support Center